Clinical Trial Update: Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 clinical trial uses PET imaging with zirconium-89 labeled trastuzumab to predict response to HER2-targeted therapy in breast cancer; the study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 89Zr-trastuzumab (zirconium-89-labeled trastuzumab)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Breast Cancer | EARLY_Phase 1 | Status: RECRUITING